PolyU proudly announced another success in our collaboration across industry and institutions in materializing uplifts in our quality of life by entering into a licensing agreement with Kinex Pharmaceuticals, Inc. (Kinex) on the commercialization of Apigenoid Flavonoid Dimer, which brings pioneering and revolutionary leaps in cancer treatments.
Apigenin Flavonoid Dimer, the MDR Locker – a breakthrough in inhibiting multidrug resistance (MDR) in cancer cells
Under the seamless collaboration among PolyU Department of Applied Biology & Chemical Technology (ABCT), McGill University, PolyU Partner State Key Laboratory of Chirosciences and PolyU Shenzhen-based State Key Laboratory for Chinese Medicine and Molecular Pharmacology, the research team led by Professor Larry Chow and Professor Bill Chan from ABCT succeeded in developing Apigenin Flavonoid Dimer as a novel inhibitor to prevent drug efflux through modified extracts from Apigenin. The Apigenin Flavonoid Dimer serves to reverse drug resistance by binding the cancer cell’s drug pump. Furthermore, it enhances the absorption of cancer drugs in the digestive system, elevating the quality of chemotherapy treatment in terms of efficacy, convenience and comfort through the oral intake of cancer drugs. The licensing of Apigenin Flavonoid Dimer was concluded in the applause over the joint signatures by PolyU Executive Vice President Mr Nicholas Yang and Kinex Chairman and CEO Dr Johnson YN Lau.
PolyU spares no effort in advancing technology transfer with the aim of propelling research constituting significant impacts on people’s quality of life. Driven by our long-established vision as well as a myriad of successful experiences, we aspire to make bolder strides in the elevation of technology ahead. Kindly refer to further details on this collaborative technological advancement here.
Apigenin Flavonoid Dimer, the MDR Locker – a breakthrough in inhibiting multidrug resistance (MDR) in cancer cells
Under the seamless collaboration among PolyU Department of Applied Biology & Chemical Technology (ABCT), McGill University, PolyU Partner State Key Laboratory of Chirosciences and PolyU Shenzhen-based State Key Laboratory for Chinese Medicine and Molecular Pharmacology, the research team led by Professor Larry Chow and Professor Bill Chan from ABCT succeeded in developing Apigenin Flavonoid Dimer as a novel inhibitor to prevent drug efflux through modified extracts from Apigenin. The Apigenin Flavonoid Dimer serves to reverse drug resistance by binding the cancer cell’s drug pump. Furthermore, it enhances the absorption of cancer drugs in the digestive system, elevating the quality of chemotherapy treatment in terms of efficacy, convenience and comfort through the oral intake of cancer drugs. The licensing of Apigenin Flavonoid Dimer was concluded in the applause over the joint signatures by PolyU Executive Vice President Mr Nicholas Yang and Kinex Chairman and CEO Dr Johnson YN Lau.
PolyU spares no effort in advancing technology transfer with the aim of propelling research constituting significant impacts on people’s quality of life. Driven by our long-established vision as well as a myriad of successful experiences, we aspire to make bolder strides in the elevation of technology ahead. Kindly refer to further details on this collaborative technological advancement here.
